LY
LYEL.US Lyell Immunopharma Inc
- Market cap
- USD 352M
- P/E
- -
- P/B
- 1.82x
- ROE
- -79.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LYEL.US undervalued?
Graham numberThe Graham number of Lyell Immunopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lyell Immunopharma Inc fundamental analysis
No fundamental analysis for Lyell Immunopharma Inc yet.
Lyell Immunopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,…
Full company profileLyell Immunopharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lyell Immunopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 657K | 7.76M | 10.7M | 84.7M | 130K | 61.0K | 36.0K | 12.0K |
| Gross Profit | 657K | 7.76M | 10.7M | 84.7M | 130K | 61.0K | -11.5M | -3.10M |
| Operating Income | -102M | -212M | -215M | -187M | -247M | -359M | -204M | -189M |
| EBITDA | -101M | -215M | -237M | -165M | -214M | -201M | -263M | -144M |
| Net Income | -129M | -204M | -250M | -183M | -235M | -343M | -274M | -153M |
| EPS | -10 | -17 | -21 | -15 | -19 | -26 | -16 | -6.24 |
| Balance Sheet | ||||||||
| Total Assets | 556M | 908M | 1.13B | 938M | 750M | 491M | 340M | 274M |
| Total Liabilities | 148M | 190M | 198M | 104M | 95.1M | 108M | 91.9M | 81.1M |
| Shareholders' Equity | 408M | 718M | 930M | 833M | 655M | 383M | 248M | 193M |
| Cash & Short-term Investments | 436M | 613M | 615M | 640M | 546M | 371M | 247M | 177M |
| Total Debt | 27.5M | 54.6M | 67.8M | 67.7M | 63.2M | 59.0M | 51.0M | 34.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | 39.5M | -161M | -126M | -170M | -164M | -162M | -150M | -143M |
| Capital Expenditure | 16.0M | 51.5M | 65.5M | 24.3M | 2.69M | 464K | 780K | 548K |
| Free Cash Flow | 23.4M | -212M | -192M | -194M | -166M | -163M | -151M | -143M |
| Ratios | ||||||||
| ROE | -31.7% | -28.5% | -26.9% | -22.0% | -35.8% | -89.6% | -110.6% | -79.2% |
| ROA | -23.3% | -22.5% | -22.2% | -19.5% | -31.3% | -69.9% | -80.7% | -55.7% |
| Net Profit Margin | -19,692.1% | -2,636.3% | -2,349.5% | -216.2% | -180,486.2% | -562,285.2% | -762,355.6% | -1,271,522.2% |
| Debt to Equity | 0.07x | 0.08x | 0.07x | 0.08x | 0.10x | 0.15x | 0.21x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lyell Immunopharma Inc dividends
Lyell Immunopharma Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Jun 2, 2025.
Who owns Lyell Immunopharma Inc
- Insiders 28.89%
- Institutions 49.18%
- Public & others 21.93%
- Shares outstanding 24.6M
- Free float 9.89M
Top funds holding LYEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 604K | 2.46% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 222K | 0.90% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 107K | 0.44% | +3.62% | Aug 2026 |
| iShares Russell 2000 Value ETF | 76.5K | 0.31% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 59.7K | 0.24% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 56.6K | 0.23% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 51.4K | 0.21% | -0.38% | Sep 2026 |
| Vanguard Russell 2000 ETF | 49.1K | 0.20% | -9.31% | Sep 2026 |
| Bridge Builder Small Cap Fund | 31.9K | 0.13% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 28.5K | 0.12% | +0.12% | Sep 2026 |
| Northern Small Cap Value | 28.4K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 25.8K | 0.10% | -0.05% | Sep 2026 |
| iShares Micro-Cap ETF | 25.6K | 0.10% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 24.9K | 0.10% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 24.0K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 21.5K | 0.09% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 19.5K | 0.08% | -14.95% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 18.3K | 0.07% | +0.20% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 17.6K | 0.07% | 0.00% | Sep 2026 |
| iShares Healthcare Innov ETF USD Acc | 17.2K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding LYEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARCH VENTURE CORP | 3.25M | 13.21% | 0.00% | Jun 2026 |
| GSK PLC | 1.51M | 6.15% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 787K | 3.20% | +9.55% | Jun 2026 |
| Orland Properties Ltd | 755K | 3.07% | 0.00% | Jun 2026 |
| BlackRock Inc | 724K | 2.95% | +277.62% | Jun 2026 |
| Almitas Capital LLC | 581K | 2.36% | +0.62% | Jun 2026 |
| Foresite Capital Management V, LLC | 476K | 1.94% | -0.15% | Jun 2026 |
| Millennium Management LLC | 367K | 1.49% | -19.92% | Jun 2026 |
| Opaleye Management Inc | 344K | 1.40% | +334.94% | Jun 2026 |
| venBio Partners LLC | 338K | 1.37% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 311K | 1.26% | +86.03% | Jun 2026 |
| Alphabet Inc | 293K | 1.19% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 189K | 0.77% | +45.27% | Sep 2026 |
| State Street Corp | 185K | 0.75% | +155.54% | Jun 2026 |
| HSG Holding Ltd | 152K | 0.62% | 0.00% | Jun 2026 |
| Northern Trust Corp | 119K | 0.48% | +291.35% | Jun 2026 |
| Qube Research & Technologies | 111K | 0.45% | +100.56% | Jun 2026 |
| Charles Schwab Investment Management Inc | 108K | 0.44% | +25.12% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 106K | 0.43% | -28.43% | Jun 2026 |
| Velan Capital Investment Management LP | 105K | 0.43% | +2.94% | Jun 2026 |
Lyell Immunopharma Inc company profile
- Company name
- Lyell Immunopharma Inc
- Ticker
- LYEL.US
- Exchange
- USA Stocks
- Listed since
- Jun 17, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Fiscal year end
- December
- Address
- 201 Haskins Way, South San Francisco, CA, United States, 94080
- Phone
- 650 695 0677
- Website
- lyell.com
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma Inc management
10- Dr. Richard D. Klausner M.D.Founder & Executive Chairman · born 1952
- Dr. Lynn Seely M.D., Ph.D.Principal Executive Officer, President, CEO & Director · born 1959
- Mr. Stephen J. Hill M.B.A.Chief Operating Officer · born 1971
- Dr. Gary K. Lee Ph.D.Chief Scientific Officer · born 1977
- Prof. Stanley R. Riddell M.D.Founder & Scientific Advisor
- Dr. Crystal L. Mackall M.D.Founder & Scientific Advisor · born 1961
- Ms. Smital Shah M.B.A.Principal Financial Officer, CFO & Chief Business Officer · born 1976
- Nellie DilleryDirector of Accounting
- Mr. Mark A. Meltz J.D.General Counsel & Corporate Secretary · born 1974
- Ms. Ann TomlinChief Human Resources Officer